Comirnaty Evrópusambandið - íslenska - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Ngenla Evrópusambandið - íslenska - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - sterum og undirstÚku hormÓn og hliÐstÆÐum - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Norditropin FlexPro Stungulyf, lausn 5/1,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 5/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 5/1,5 mg/ml

Norditropin FlexPro Stungulyf, lausn 15/1,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 15/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 15/1,5 mg/ml

Norditropin FlexPro Stungulyf, lausn 10/1,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 10/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 10/1,5 mg/ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 5 mg /1,5 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 5 mg /1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 5 mg /1,5 ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 15 mg/1,5 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 15 mg/1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 15 mg/1,5 ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 10 mg/1,5 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 10 mg/1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 10 mg/1,5 ml

Medikinet Tafla 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

medikinet tafla 10 mg

medice arzneimittel pütter gmbh & co. kg* - methylphenidatum hýdróklóríð - tafla - 10 mg

Medikinet Tafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

medikinet tafla 20 mg

medice arzneimittel pütter gmbh & co. kg* - methylphenidatum hýdróklóríð - tafla - 20 mg